DrugsNews.net

Drugs Xagena

Xagena Mappa
Xagena Newsletter
OncologiaMedica.net
Reumabase.it

Search results for "Bortezomib"

The European Medicines Agency’s Committee for Medicinal Products for Human Use ( CHMP ) has recommended marketing authorisation for Pomalidomide Celgene ( Imnovid ) to treat patients with multiple mye ...


The Committee for Medicinal Products for Human Use ( CHMP ) has adopted a positive opinion recommending a variation to the terms of the marketing authorisation for the medicinal product Velcade ( Bort ...


Multiple myeloma, a cancer of white blood cells predominantly affecting the bone marrow, impacts approximately 1 to 5 in every 100,000 people worldwide each year. With a five-year survival rate of 44% ...


The FDA ( Food and Drug Administration ) has approved Kyprolis ( Carfilzomib ) to treat patients with multiple myeloma who have received at least two prior therapies, including treatment with Velcade ...


The FDA ( Food and Drug Administration ) has approved Velcade ( Bortezomib ) for the retreatment of adult patients with multiple myeloma who had previously responded to Bortezomib therapy and relapsed ...


The European Commission ( EU ) has approved a variation to the terms of the marketing authorisation of Velcade ( Bortezomib ) in combination with Rituximab, Cyclophosphamide, Doxorubicin and Prednison ...


The ASCO Task Force has applied the Framework to four clinical scenarios in which multiple trials have compared new treatment options with current standards of care: first-line treatment for metastati ...


The Chemotherapy Clinical Reference Group ( CRG ) has reviewed drugs and drug indications for inclusion on the National cancer drugs fund list. The decision summaries record how each drug/drug indica ...


The FDA ( Food and Drug Administration ) has granted a Breakthrough Therapy Designation to the immunotherapy Darzalex ( Daratumumab ) in combination with Lenalidomide ( Revlimid ), an immunomodulatory ...


The FDA ( Food and Drug Administration ) has granted accelerated approval to Xpovio ( Selinexor ) in combination with Dexamethasone for adult patients with relapsed or refractory multiple myeloma ( RR ...


The FDA ( U.S. Food and Drug Administration ) has approved Darzalex Faspro ( Daratumumab and Hyaluronidase-fihj ), a subcutaneous formulation of Daratumumab, in combination with Bortezomib, Cyclophos ...